Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
Since dendritic cells operate as professional antigen-presenting cells (APCs) and hence are capable of jumpstarting the immune system, they have been exploited to develop a variety of immunotherapeutic regimens against cancer. In the few past years, myeloid-derived suppressor cells (MDSCs) have been shown to mediate robust immunosuppressive functions, thereby inhibiting tumor-targeting immune responses. Thus, we propose that the immunomodulatory activity of MDSCs should be carefully considered for the development of efficient anticancer immunotherapies.
Rayne Institute; University College London; London, UK ; Navarrabiomed-Fundacion Miguel Servet; Complejo Hospitalario de Navarra; Pamplona, Spain.
David
D
Escors
Therese
T
Liechtenstein
Noemi
N
Perez-Janices
Julia
J
Schwarze
Ines
I
Dufait
Cleo
C
Goyvaerts
Alessio
A
Lanna
Frederick
F
Arce
Idoia
I
Blanco-Luquin
Grazyna
G
Kochan
David
D
Guerrero-Setas
Karine
K
Breckpot
T cells; antigen presentation; cancer; dendritic cells; myeloid-derived suppressor cell